BRISBANE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that Howard B. Rosen has resigned from the Company’s Board of Directors, effective immediately. Mr. Rosen, who is also Vice President, Commercial Strategy at Gilead Sciences, Inc., has served on the CoTherix Board of Directors since September 2005. On October 2, 2006, Gilead announced that it signed a definitive agreement to acquire Myogen, Inc.
Donald J. Santel, Chief Executive Officer of CoTherix, Inc., stated, “Howie Rosen contributed greatly to this Board of Directors. I am very grateful for his significant efforts, and am joined by the other directors in wishing him well.”
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular disease. CoTherix currently markets Ventavis(R) (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). The Company is also developing fasudil, a rho-kinase inhibitor, for the treatment of PAH and stable angina. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG. More information can be found at www.cotherix.com or www.4ventavis.com.
CoTherix, Inc.
CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551; or media, Jason Farber, jfarber@burnsmc.com, orinvestors, Clay Kramer, ckramer@burnsmc.com, both of Burns McClellan, Inc.,+1-212-213-0006, for CoTherix, Inc.
Web site: http://www.cotherix.com/
